Methods Used for Ovary Suppression in Women with Breast Cancer
Harold J. Burstein, MD, PhD, a medical oncologist at the Dana-Farber Cancer Institute, explains how ovary suppression is done in patients with breast cancer. This is a particularly important treatment for younger women who still wish to have children one day.
Harold J. Burstein, MD, PhD, a medical oncologist at the Dana-Farber Cancer Institute, explains how ovary suppression is done in patients with breast cancer. This is a particularly important treatment for younger women who still wish to have children one day.
Ovary suppression can be done in 1 of 2 ways, and both have proven successful in a number of cases and trials. The first option is to completely remove the ovaries surgically. This is not the preferred method, but it has become a standard when a patient does not wish to continue with the second option.
The other way to perform ovary suppression involves gonadotropin-releasing hormone (GnRH) agonist drugs given via injections monthly or once every 3 months. The is typically used first in younger women and tolerance to the drugs will be displayed between 6-12 months of the initial shot. From there, patients can choose to stay on this treatment plan or have the ovaries surgically removed.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
